nVision Medical is a clinical stage medical device company dedicated to filling the void in female health-related innovation.  In November 2015 nVision received 510k approval from the FDA for a novel device used for the early stage detection of ovarian cancer.

nVision completed a $4 million Series A financing led by Catalyst Heath Ventures in 2013 and a $12 million Series B financing led by Arboretum Ventures in 2016.

In April 2018, Boston Scientific (NYSE: BSX) announced the acquisition of nVision Medical for $275 million.

Founder and CEO:

Surbhi Sarna

Ted was an incredibly supportive value-added investor in both our Series A financing in 2013 and our Series B financing in 2016. Ted was a great sounding board for me, he provided honest direct feedback on different potential growth alternatives.
— Surbhi Sarna, Founder and CEO